Key Takeaways Novartis (NVS) shares tumbled nearly 4% following the failure of its high-stakes cardiovascular drug pelacarsen in a Phase III trial, marking the...
Market Samachar is a news aggregator. This article was originally published by thestockmarketwatch.com. Tap the button above to read the full story on their site.